Meta-analysis studies demonstrated that low levels of adiponectin are correlated to a higher risk of postmenopausal breast cancer (154) and increased adiponectin serum levels confered a protective effect on endometrial cancer (155). This evidence concerns the gene ADIPOQ and breast carcinoma.